Table 2. Efficacy endpoints at week 4 per-protocol population and intent to treat population.

OTE, Overall treatment effect.

Endpoint	Acotiamide n (%)	Mosapride n (%)	Difference (95% CI)	Acotiamide vs Mosapride (p-value)
(A) Per-Protocol Population
Primary Endpoint
Responder rate by using OTE	98.00	93.27	4.7 (-0.8 - 10.3)	0.1707
Secondary Endpoints Elimination Rate
Postprandial fullness	15.00	9.62	-5.4 (-14.4 - 3.6)	0.2883
Upper abdominal bloating	16.00	14.42	-1.6 (-11.4 - 8.3)	0.8460
Early satiation	11.00	13.46	2.5 (-6.5 - 11.4)	0.6718
(B) Intent to Treat Population
Primary Endpoint
Responder rate by using OTE	95.15	89.91	5.2 (-1.8 - 12.3)	0.1954
Secondary Endpoints Elimination Rate
Postprandial fullness	14.56	9.17	-5.4 (-14.1, 3.3)	0.2875
Upper abdominal bloating	15.53	13.76	-1.8 (-11.3, 7.8)	0.8462
Early satiation	10.68	12.84	2.2 (-6.5, 10.8)	0.6744